Evidence map›Paper›PMID 40351068›Full record

ArticleMedicinal chemistry (Shariqah (United Arab Emirates))2025

Deeksha Sarojini Devi Radhakumar, Sundar Thiyagarajan, Kaushik Rajaram, Rajesh Parsanathan

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry (Shariqah (United Arab Emirates)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Deeksha Sarojini Devi RadhakumarDepartment of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Neelakudi, Thiruvarur, Tamil Nadu, 610 005, India.
Sundar ThiyagarajanDepartment of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Neelakudi, Thiruvarur, Tamil Nadu, 610 005, India.
Kaushik RajaramDepartment of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Neelakudi, Thiruvarur, Tamil Nadu, 610 005, India.
Rajesh ParsanathanDepartment of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Neelakudi, Thiruvarur, Tamil Nadu, 610 005, India.ORCID 0000-0001-8973-3507

Funding

Department of Biotechnology (DBT), Ministry of Science and Technology, Govt. of India BT/HRD/35/02/2006
6 · The paper itself

Abstract

backgroundMonkeypox, a viral zoonotic disease akin to smallpox, has posed significant public health challenges, particularly in Africa. Recent outbreaks, including those in India, underscore the global threat it poses.

objectiveIn this study, we explore a novel approach to combat monkeypox virus (MPXV) infection by targeting its surface proteins, crucial for viral entry and fusion.

methodsEmploying advanced computational techniques, we predict and refine the 3D structures of MPXV surface proteins and human antimicrobial peptides (hAMPs), specifically Histatin 1, 3, and their cleaved product, Histatin 5 (HIS 5). Further, molecular docking was carried out for MPXV surface proteins with hAMP HIS using HDOCK and Cluspro 2.0. Protein-peptide interactions were analyzed using PdbSum. Finally, the physicochemical properties of HIS peptides were determined using CamSol.

resultsOur findings suggest HIS 5 as a potential therapeutic peptide against MPXV, warranting further investigation through

conclusionThis study sheds light on the efficacy of the HIS family in targeting MPXV and advocates for continued exploration of HIS 5's antiviral effects.

Indexed as

Antimicrobial Cationic PeptidesAntimicrobial PeptidesAntiviral AgentsHistatinsMolecular Docking SimulationMonkeypox virusAmino Acid SequenceComputer SimulationHumansAntimicrobial Cationic PeptidesAntimicrobial PeptidesAntiviral AgentsHistatinsantimicrobial peptides.histatin 5human antimicrobial peptidesmolecular dockingMonkeypox viruspeptide therapy

Identifiers

PMID40351068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.